THE PROGNOSTIC IMPLICATIONS OF LOW SERUM CA-125 LEVELS PRIOR TO THE 2ND-LOOK OPERATION FOR STAGE-III AND STAGE-IV EPITHELIAL OVARIAN-CANCER

被引:18
作者
GALLION, HH
HUNTER, JE
VANNAGELL, JR
AVERETTE, HE
CAIN, JM
COPELAND, LJ
HIGGINS, RV
HUSSEINZADEH, N
NAHHAS, WA
PARTRIDGE, EE
PURSELL, SH
机构
[1] UNIV WASHINGTON,MED CTR,SEATTLE,WA 98195
[2] UNIV CINCINNATI,CINCINNATI,OH 45221
[3] WRIGHT STATE UNIV,SCH MED,DAYTON,OH 45435
[4] UNIV ALABAMA,BIRMINGHAM,AL 35294
[5] UNIV LOUISVILLE,SCH MED,LOUISVILLE,KY 40292
关键词
D O I
10.1016/0090-8258(92)90190-T
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Second-look laparotomy is performed to evaluate response to chemotherapy and to determine the need for additional treatment. The relationship between absolute levels of serum CA 125 <35 u/ml and disease status at second-look operation was evaluated in 95 patients with advanced-stage epithelial ovarian cancer. Eighty-six patients had Stage III disease and nine patients had Stage IV cancer. Residual tumor was documented at second-look laparotomy in 52 (55%) of the patients studied. Forty-nine percent of the 82 patients with serum CA 125 values <20 u/ml had residual disease. In contrast, 12 of 13 (92%) patients with serum CA 125 values of 20-35 u/ml had residual tumor at second-look laparotomy. All patients with serous cystadenocarcinomas and serum CA 125 values of 20-35 u/ml had residual tumor, and two-thirds of these cases had grossly visible disease. The positive predictive value of a serum CA 125 level of 20-35 u/ml was 0.92. These data suggest that second-look laparotomy should be deferred in patients with advanced-stage ovarian cancer until serum CA 125 values are less than 20 u/ml. © 1992.
引用
收藏
页码:29 / 32
页数:4
相关论文
共 14 条
[1]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[2]   REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA [J].
BAST, RC ;
FEENEY, M ;
LAZARUS, H ;
NADLER, LM ;
COLVIN, RB ;
KNAPP, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1331-1337
[3]   CA-125 SERUM LEVELS CORRELATED WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS [J].
BEREK, JS ;
KNAPP, RC ;
MALKASIAN, GD ;
LAVIN, PT ;
WHITNEY, C ;
NILOFF, JM ;
BAST, RC .
OBSTETRICS AND GYNECOLOGY, 1986, 67 (05) :685-689
[4]   2ND THOUGHTS ABOUT 2ND-LOOK LAPAROTOMY IN ADVANCED OVARIAN-CANCER [J].
FRIEDMAN, JB ;
WEISS, NS .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (15) :1079-1082
[5]   ANOTHER LOOK AT THE 2ND-ASSESSMENT PROCEDURE FOR OVARIAN EPITHELIAL CARCINOMA [J].
GALLUP, DG ;
TALLEDO, OE ;
DUDZINSKI, MR ;
BROWN, KW .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, 157 (03) :590-596
[6]  
JACOBS I, 1989, HUM REPROD, V4, P1
[7]  
KLUG TL, 1984, CANCER RES, V44, P1048
[8]   USE OF CA 125 MONOCLONAL-ANTIBODY TO MONITOR PATIENTS WITH OVARIAN-CANCER [J].
KUDLACEK, S ;
SCHIEDER, K ;
KOLBL, H ;
NEUNTEUFEL, W ;
NOWOTNY, C ;
BREITENECKER, G ;
BIEGELMAYER, G ;
VETTERLEIN, M ;
FURLINGER, B ;
MICKSCHE, M .
GYNECOLOGIC ONCOLOGY, 1989, 35 (03) :323-329
[9]  
MILLER DS, 1986, CANCER, V57, P530, DOI 10.1002/1097-0142(19860201)57:3<530::AID-CNCR2820570321>3.0.CO
[10]  
2-5